v3.25.4
Segments - Schedule of Segment Revenue and Expenses to Consolidated Net Loss (Income) (Details) - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Segment Reporting Information [Line Items]    
Product revenue, net $ 0 $ 87,371,000
Less :    
Cost of sales 0 5,953,000
Direct research and development expenses by program:    
Acquired in-process research and development 0 36,203,000
Selling, general and administrative 62,887,000 114,331,000
Restructuring expenses 0 22,851,000
(Benefit) provision for income taxes 46,000 (393,000)
Interest income (9,302,000) (13,809,000)
Net loss (144,735,000) (301,743,000)
Operating Segments [Member]    
Segment Reporting Information [Line Items]    
Product revenue, net 0 87,371,000
Less :    
Cost of sales [1],[2],[3] 0 124,633,000
Direct research and development expenses by program:    
Acquired in-process research and development [1],[2] 0 36,203,000
Personnel-related research and development [1],[2],[4] 32,284,000 38,976,000
Selling, general and administrative [1],[2] 62,887,000 114,331,000
Restructuring expenses [1],[2] 0 22,851,000
(Benefit) provision for income taxes [1],[2] 46,000 (393,000)
Interest income [1],[2] (9,302,000) (13,809,000)
Other segment items [1],[2],[5] 700,000 1,214,000
Net loss (144,735,000) (301,743,000)
Operating Segments [Member] | Avexitide    
Direct research and development expenses by program:    
Total direct research and development expenses by program [1],[2] 24,100,000 2,766,000
Operating Segments [Member] | AMX0035 - PSP    
Direct research and development expenses by program:    
Total direct research and development expenses by program [1],[2] 17,260,000 16,917,000
Operating Segments [Member] | AMX0035 - ALS    
Direct research and development expenses by program:    
Total direct research and development expenses by program [1],[2] 1,756,000 36,727,000
Operating Segments [Member] | Other programs    
Direct research and development expenses by program:    
Total direct research and development expenses by program [1],[2] $ 15,004,000 $ 8,698,000
[1] Depreciation and amortization expense of $0.5 million and $0.9 million during the years ended years ended December 31, 2025 and 2024, respectively, are allocated across the significant expense captions.
[2] The significant expense categories and amounts align with the segment-level information that is regularly provided to the CODM. As the Company has one reportable segment, there were no intersegment eliminations for the years ended December 31, 2025 and 2024.
[3] Includes inventory impairment and loss on firm purchase commitments of zero and $118.7 million during years ended December 31, 2025 and 2024, respectively.
[4] The Company does not allocate personnel and other similar costs to specific programs because these costs are deployed across multiple programs.
[5] Other segment items primarily consists of net realized and unrealized losses on foreign exchange transactions